Arūnas Girčys

FDA Approval Summary: Osimertinib for Adjuvant Treatment of Surgically Resected Non–Small Cell Lung Cancer, a Collaborative Project Orbis Review

Jiang Liu, R. Pazdur, U. Rohr, 2021, Clinical Cancer Research.